Literature DB >> 7579051

Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease.

D D Ivy1, E M Shaffer, A M Johnson, W J Kimberling, A Dobin, P A Gabow.   

Abstract

It is known that adults with autosomal dominant polycystic kidney disease (ADPKD) have an increased incidence of cardiovascular abnormalities, including mitral valve prolapse. The cardiac manifestations of ADPKD in the pediatric population have not been well established. To determine the cardiac manifestations of children with ADPKD, echocardiography was performed in 154 children of 66 families in which one parent has ADPKD. Eighty-six affected children and 68 unaffected children were evaluated in a prospective, single-blinded manner by echocardiography. Affected children were defined as those with any cysts on a concurrent renal ultrasound or those predicted to be gene carriers by gene linkage analysis. A 12% incidence of mitral valve prolapse was found in the affected children compared with only 3% of the unaffected children (P < 0.05). ADPKD children, but not their unaffected siblings, demonstrate a significant correlation between left ventricular mass index and systolic blood pressure. Moreover, hypertensive ADPKD children have significantly larger left ventricular mass index than do normotensive ADPKD children. A 3.5% incidence of congenital heart disease was found in the affected group, whereas 2.9% of the unaffected children had congenital heart disease. It was concluded that systemic manifestations of ADPKD, particularly cardiovascular abnormalities, are present even in childhood and these warrant the clinician's attention.

Entities:  

Mesh:

Year:  1995        PMID: 7579051     DOI: 10.1681/ASN.V5122032

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

1.  Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways.

Authors:  Ivana Y Kuo; Andrea T Kwaczala; Lily Nguyen; Kerry S Russell; Stuart G Campbell; Barbara E Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

2.  Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science Perspective.

Authors:  Shobha Ratnam; Surya M Nauli
Journal:  Int J Nephrol Urol       Date:  2010

Review 3.  Autosomal dominant polycystic kidney disease in children.

Authors:  Melissa A Cadnapaphornchai
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

4.  Primary cilia defects causing mitral valve prolapse.

Authors:  Katelynn A Toomer; Mengyao Yu; Diana Fulmer; Lilong Guo; Kelsey S Moore; Reece Moore; Ka'la D Drayton; Janiece Glover; Neal Peterson; Sandra Ramos-Ortiz; Alex Drohan; Breiona J Catching; Rebecca Stairley; Andy Wessels; Joshua H Lipschutz; Francesca N Delling; Xavier Jeunemaitre; Christian Dina; Ryan L Collins; Harrison Brand; Michael E Talkowski; Federica Del Monte; Rupak Mukherjee; Alexander Awgulewitsch; Simon Body; Gary Hardiman; E Starr Hazard; Willian A da Silveira; Baolin Wang; Maire Leyne; Ronen Durst; Roger R Markwald; Solena Le Scouarnec; Albert Hagege; Thierry Le Tourneau; Peter Kohl; Eva A Rog-Zielinska; Patrick T Ellinor; Robert A Levine; David J Milan; Jean-Jacques Schott; Nabila Bouatia-Naji; Susan A Slaugenhaupt; Russell A Norris
Journal:  Sci Transl Med       Date:  2019-05-22       Impact factor: 17.956

Review 5.  Hypertension in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; Konrad Stepniakowski; Frederic Rahbari-Oskoui
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

Review 6.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

7.  Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants.

Authors:  Melissa A Cadnapaphornchai; Diana M George; Amirali Masoumi; Kim McFann; John D Strain; Robert W Schrier
Journal:  Contemp Clin Trials       Date:  2011-01-23       Impact factor: 2.226

8.  Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?

Authors:  Shigeo Horie
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

9.  Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease.

Authors:  Imed Helal; Berenice Reed; Pamela Mettler; Kim Mc Fann; Oleksandra Tkachenko; Xiang-Dong Yan; Robert W Schrier
Journal:  Am J Nephrol       Date:  2012-10-04       Impact factor: 3.754

Review 10.  Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.